Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood tests could guide oxygen therapy for severe brain injury

NCT ID NCT04855396

Knowledge-focused Sponsor: University of Michigan Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether certain proteins in the blood can help doctors monitor severe traumatic brain injury and predict who might benefit from hyperbaric oxygen therapy. Researchers will analyze blood samples from 150 patients already enrolled in a larger trial testing different doses of hyperbaric oxygen. The goal is to find reliable markers that could make future treatment more personalized and clinical trials more effective.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
hyperbaric oxygen therapy
What this could lead to
If successful, this could help doctors tailor hyperbaric oxygen therapy to individual patients and make future clinical trials more efficient.
What could go wrong
This is an observational study that does not directly test a treatment. The findings may not lead to improved outcomes or may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2021

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The investigators plan to enroll a maximum of 150 male and female subjects among multiple clinical sites.

Ages

16 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Enrolled in HOBIT (this is an ancillary study to the HOBIT Trial) Exclusion Criteria: * Profoundly anemic (subjects who are profoundly anemic require blood transfusion) * Blood samples cannot be obtained

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Traumatic brain injury are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Brain Injuries, Traumatic Charcot-Marie-Tooth disease type 1F traumatic brain injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Traumatic brain injury

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    11 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Detroit Receiving Hospital

    RECRUITING

    Detroit, Michigan, 48201, United States

  • Duke University Hospital

    NOT_YET_RECRUITING

    Durham, North Carolina, 27710, United States

  • Hamilton General Hospital

    SUSPENDED

    Hamilton, Ontario, L8L 2X2, Canada

  • Hennepin County Medical Center

    RECRUITING

    Minneapolis, Minnesota, 55415, United States

  • OSU Wexner Medical Center

    SUSPENDED

    Columbus, Ohio, 43210, United States

  • St. Mary's Medical Center

    SUSPENDED

    West Palm Beach, Florida, 33407, United States

  • UCSD Medical Center - Hillcrest Hospital

    RECRUITING

    San Diego, California, 92103, United States

  • University of Iowa Hospitals & Clinics

    RECRUITING

    Iowa City, Iowa, 52242, United States

  • University of Kentucky Hospital

    RECRUITING

    Lexington, Kentucky, 40536, United States

  • University of Maryland Medical Center

    RECRUITING

    Baltimore, Maryland, 21201, United States

  • University of Nebraska Medical Center

    SUSPENDED

    Omaha, Nebraska, 68198, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.